Fig. 1From: PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 studyStudy flow. *2, 2, 2, 4, 4, and 4 patients were assigned to receive placebo at a dose and frequency of 75 mg Q4W, 150 mg Q4W, 150 mg Q8W, 300 mg Q8W, 300 mg Q12W, and 450 mg Q12W, respectivelyBack to article page